Senti Biosciences, Inc.

Contributing Author

Recent Articles by Senti Biosciences, Inc.

Jun-30	Senti Bio Participates in Nasdaq Amplify Spotlight Series SNTI GlobeNewswire
Jun-24	Senti Bio to Present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference SNTI GlobeNewswire
Jun-18	Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia SNTI GlobeNewswire
Jun-09	Senti Biosciences Announces New Employment Inducement Grants SNTI GlobeNewswire
Jun-06	Senti Bio to Participate in a Virtual Fireside Chat Hosted by Chardan Capital Markets, LLC SNTI GlobeNewswire
May-22	Senti Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar SNTI GlobeNewswire
May-22	Senti Bio Receives Additional $1.0 Million Tranche from California Institute for Regenerative Medicines (CIRM) Grant for Advancing Clinical Development of SENTI-202 SNTI GlobeNewswire
May-08	Senti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 SNTI GlobeNewswire
May-06	Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development SNTI GlobeNewswire
May-01	Senti Bio Releases Virtual Investor "What This Means" Segment SNTI GlobeNewswire
Apr-30	Senti Bio to Present at the Citizens JMP Life Sciences Conference SNTI GlobeNewswire
Apr-30	Senti Bio to Present at the Citizens JMP Life Sciences Conference SNTI GlobeNewswire